PhRMA panel: US post-election 'big bang' to impact biopharma long term
This article was originally published in Scrip
Executive Summary
With the outcome of the 2012 congressional and presidential races not yet known, the biopharmaceutical industry cannot afford to take sides, advised health care policy and government affairs expert Chris Jennings, president of Washington-based Jennings Policy Strategies.